Imagenomix

Principal Investigators: Aris Tsirigos, PhD/Matija Snuderl, MD/Daniel Orringer, MD

Imagenomix Corp (IGX) is at the forefront of innovation in the biotechnology sector, specializing in the rapid detection of cancer-causing mutations using artificial intelligence. Founded as a spin-off from New York University, IGX is driven by a mission to revolutionize cancer diagnostics and enhance patient outcomes through cutting-edge technology.

IGX leverages its proprietary AI algorithms to analyze Hematoxylin and Eosin (H&E) stained slides, a standard method in pathology, for the swift identification of genetic mutations associated with cancer. This groundbreaking approach offers significant advantages in speed and accuracy compared to traditional diagnostic methods.